Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Velcade enters phase II trial in NSCLC

Jan. 17, 2003

AT-3639: new quinolone with antitumor activity generally comparable to etoposide

Jan. 17, 2003

Schering scientists present CDK and GSK-3 inhibitors for cancer and other uses

Jan. 17, 2003

Novartis researchers describe novel proteasome inhibitors

Jan. 17, 2003

Caelyx approved in E.U. for metastatic breast cancer

Jan. 16, 2003

Preclinical antitumor profile of ST-1481, a new camptothecin derivative

Jan. 16, 2003

Phase II trial of Advexin plus radiation shows tumor regression in NSCLC

Jan. 16, 2003

Enzon suspends PEG-paclitaxel development program

Jan. 15, 2003

PI-166 enters phase Ib trial for liver cancer

Jan. 15, 2003

Bayer acquires antibody license from MorphoSys

Jan. 15, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 7, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 7, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.